Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Reduced Brain-Derived Neurotrophic Factor (BDNF) levels have been described in a number of patho-physiological conditions, most notably, in Huntington's disease (HD), a progressive neurodegenerative disorder. Since BDNF is also produced in blood, we have undertaken the measurement of its peripheral levels in the attempt to identify a possible link with HD prognosis and/or its progression. Here we evaluated BDNF level in 398 blood samples including 138 controls, 56 preHD, and 204 HD subjects. We found that BDNF protein levels were not reliably different between groups, whether measured in plasma (52 controls, 26 preHD, 105 HD) or serum (39 controls, 5 preHD, 29 HD). Our experience, and a re-analysis of the literature highlighted that intra-group variability and methodological aspects affect this measurement, especially in serum. We also assessed BDNF mRNA levels in blood samples from 47 controls, 25 preHD, and 70 HD subjects, and found no differences among the groups. We concluded that levels of BDNF in human blood were not informative (mRNA levels or plasma protein level) nor reliable (serum protein levels) as HD biomarkers. We also wish to warn the scientific community in interpreting the significance of changes measured in BDNF protein levels in serum from patients suffering from different conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 mRNA levels of other HD-related genes in control and HD patients. Samples are from Italian Cohort C. Blood mRNA levels of (A) ANXA1 and (B) ROCK1 were measured with two different normalisation strategies (ß-actin mRNA levels (ß-ACT), according to [25], and EAR levels, according to [24].](https://figures.cochat.ai/paper-figures/0e1f7bacf29a461f9f513e18e813b527/brain-derived-neurotrophic-factor-in-patients-with-huntington-s-disease-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Key biomarkers include polyQ-Htt and Tau, which are detected in the CSF, as well as BDNF, which is measurable in the blood [253,254,255,256].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [256]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123 · cited 1×
“This is not due to the ELISA assay itself that has been extensively validated in cells, brain tissue and plasma samples [22,23,32].”
BackgroundSelf-citationBrain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947 · cited 4×
“We previously demonstrated that transcription from the BDNF promoters II, IV, and VI was reduced in the brains of HD animal models and in human postmortem brain tissue [10].”
BackgroundInfluentialSelf-citationThe impact of age, weight and gender on BDNF levels in human platelets and plasma
Lommatzsch, M., Zingler, D., Schuhbaeck, K., Schloetcke, K., Zingler, C., Schuff-Werner, P., & Virchow, J. C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.002 · Cited by 842 · cited 3×
“, (2005) have shown that different types of blood collection tubes (EDTA or heparin-treated) can influence the BDNF content detected in plasma [17].”
BackgroundLangbehn, D., Brinkman, R., Falush, D., Paulsen, J., Hayden, M., & on behalf of an International Huntington's Disease Collaborative Group (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00241.x · Cited by 817 · cited 2×
“For each pre-HD individual, the estimated probability of onset within the next 5 years was calculated on the basis of the number of CAG repeats and his/her present age, according to Langbehn [19].”
MethodIndividuality and variation in gene expression patterns in human blood
Whitney, A. R., Diehn, M., Popper, S. J., Alizadeh, A. A., Boldrick, J. C., Relman, D. A., & Brown, P. O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252784499 · Cited by 778 · cited 1×
“Furthermore, microarray studies on blood samples from healthy subjects have shown intra-individual variation in the expression of several genes due to differences in the relative proportions of specific blood cell subsets, gender, age, and the time of day at which the blood was sampled [34].”
BackgroundBrain-derived Neurotrophic Factor Is Stored in Human Platelets and Released by Agonist Stimulation
Fujimura, H., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi, J.-I., Sun, B., Altar, C., & Tandon, N. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613072 · Cited by 777
Blood BDNF Concentrations Reflect Brain-Tissue BDNF Levels across Species
Klein, A. B., Williamson, R., Santini, M. A., Clemmensen, C., Ettrup, A., Rios, M., Knudsen, G. M., & Aznar, S. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000738 · Cited by 726 · cited 1×
“BDNF has been detected also in the blood [6,7,8].”
BackgroundPruunsild, P., Kazantseva, A., Aid, T., Palm, K., & Timmusk, T. (2007) · Genomics · doi:10.1016/j.ygeno.2007.05.004 · Cited by 699 · cited 1×
“The human BDNF gene is characterised by very complex regulation as it contains nine different promoters that act independently to modulate the transcription of BDNF mRNA in a stimulus- and time- specific manner [33].”
Background
Cited by
Mesenchymal Stem Cells for Neurological Disorders
Andrzejewska, A., Dabrowska, S., Lukomska, B., & Janowski, M. (2021) · Advanced Science · doi:10.1002/advs.202002944 · Cited by 359
Numakawa, T., Odaka, H., & Adachi, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113650 · Cited by 353
“Although correlations between serum levels of BDNF and HD have been controversial, a recent report concluded that levels of BDNF mRNA/protein in human blood samples were not suitable for biomarkers of HD [158].”
BackgroundTrkB Receptor Signalling: Implications in Neurodegenerative, Psychiatric and Proliferative Disorders
Gupta, V., You, Y., Gupta, V., Klistorner, A., & Graham, S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510122 · Cited by 258
“It is also susceptible to proteolytic cleavage and does not have a long half life in blood [119].”
BackgroundPolacchini, A., Metelli, G., Francavilla, R., Baj, G., Florean, M., Mascaretti, L. G., & Tongiorgi, E. (2015) · Scientific Reports · doi:10.1038/srep17989 · Cited by 263
Haile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
“…240 min r = −0.897, p = 0.002 r = −0.791, p = 0.038 r = −0.944, p = 0.001 r = −0.777, p = 0.023 r = −0.659, p = 0.098 334 C. N. Haile et al. serum BDNF, because of concerns regarding stability and reliability of using serum as an assay medium for BDNF (Fujimura et al., 2002; Zuccato et al., 2011).”
MethodInfluentialMaiti, P., & Dunbar, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061637 · Cited by 233
Chong, H. X., Yusoff, N. A. A., Hor, Y.-Y., Lew, L.-C., Jaafar, M. H., Choi, S.-B., Yusoff, M. S. B., Wahid, N., Abdullah, M. F. I. L., Zakaria, N., et al. (2019) · Beneficial Microbes · doi:10.3920/bm2018.0135 · Cited by 206
Sun, D., Wurzelmann, M., & Romeika, J. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.198964 · Cited by 184
“Clinical studies have shown a causal relationship between lower levels of BDNF and cognitive declines observed in aging, schizophrenia, and Rett syndrome (Zuccato et al., 2011; Autry and Monteggia, 2012; Soares et al., 2016).”
Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum
Naegelin, Y., Dingsdale, H., Säuberli, K., Schädelin, S., Kappos, L., & Barde, Y.-A. (2018) · eneuro · doi:10.1523/eneuro.0419-17.2018 · Cited by 151
“However, whether or not BDNF levels can be reliably determined in human serum is increasingly a matter of debate (Zuccato et al., 2011).”
BackgroundResultInfluentialSandrini, L., Di Minno, A., Amadio, P., Ieraci, A., Tremoli, E., & Barbieri, S. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082281 · Cited by 137
“Concerning methodological aspects, it is well-known that different anticoagulants, temperatures, and delays in sample centrifugation, as well as conditions and time of sample storage influence the measurements of BDNF [46,51,53,61].”
BackgroundBrain-derived neurotrophic factor: Regulation, effects, and potential clinical relevance
Benarroch, E. E. (2015) · Neurology · doi:10.1212/wnl.0000000000001507 · Cited by 135
Circadian and sleep disorder in Huntington's disease
Morton, A. J. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.014 · Cited by 154
Jin, J., Albertz, J., Guo, Z., Peng, Q., Rudow, G., Troncoso, J. C., Ross, C. A., & Duan, W. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12190 · Cited by 119
“dysregulation, mitochondrial dysfunction, increased oxidative stress, excitotoxicity, and neurotrophic factor deficiency have been implicated in HD pathogenesis (Panov et al. 2002; Cui et al. 2006; Bithell et al. 2009; Giralt et al. 2009; Rosenstock et al. 2010; Xie et al. 2010; Ross and Tabrizi 2011; Zuccato et al. 2…”
BackgroundEwald, E. R., Wand, G. S., Seifuddin, F., Yang, X., Tamashiro, K. L., Potash, J. B., Zandi, P., & Lee, R. S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.003 · Cited by 105
“Specifically, it is not clear whether other genes that are important for mood disorders and have been demonstrated to be expressed in lymphocytes, such as Crh, Gr, and Bdnf (Baker et al., 2003, Zuccato et al., 2011, Maranville et al., 2013), exhibit similar across-tissue, CpG-to-CpG correlations.”
BackgroundFailla, M. D., Conley, Y. P., & Wagner, A. K. (2015) · Neurorehabilitation and neural repair · doi:10.1177/1545968315586465 · Cited by 110
Reidling, J. C., Relaño-Ginés, A., Holley, S. M., Ochaba, J., Moore, C., Fury, B., Lau, A., Tran, A. H., Yeung, S. Y., Salamati, D., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.11.005 · Cited by 104
“Diminished BDNF levels are present in HD mice and in human HD subjects (Strand et al., 2007; Zuccato et al., 2011), and many efficacious treatments in HD mice show a concomitant increase in BDNF (Ross and Tabrizi, 2011).”
BackgroundSmith, G. A., Rocha, E. M., McLean, J. R., Hayes, M. A., Izen, S. C., Isacson, O., & Hallett, P. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu166 · Cited by 95
“Altered levels of neurotransmitters are detected throughout the basal ganglia of HD patients (15,30).”
Zuccato, C., & Cattaneo, E. F. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-45106-5_14 · Cited by 100
“2007) in our experience, the detection of BDNF in human blood samples remains extremely complex and variable and results can be easily affected by the experimental procedure (Marullo et al. 2010; Zuccato et al. 2011).”
BackgroundSelf-citationAmphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders
Rakotoarisoa, M., & Angelova, A. (2018) · Medicines · doi:10.3390/medicines5040126 · Cited by 82
“Symptoms develop from a general lack of coordination to apparent uncoordinated, jerky body movements [11].”
BackgroundProteotoxicity and Neurodegenerative Diseases
Ruz, C., Alcantud, J. L., Montero, F. V., Durán, R., & Bandrés‐Ciga, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165646 · Cited by 89
“Huntington’s disease Huntingtin PolyQ Intracellular (cytosolic and nuclear) Plasma-membrane integrity disruption Transcriptional dysregulation Reduced levels of neurotrophic factors as BDNF Impairment of protein degradation systems Mitochondrial dysfunction Reactive gliosis Neuroinflammation Cell death [4] [5] [6] [7,…”
BackgroundMirnas as Biomarkers of Neurodegenerative Disorders
Viswambharan, V., Thanseem, I., Vasu, M. M., Poovathinal, S. A., & Anitha, A. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0242 · Cited by 89
Lambuk, L., Lazaldin, M. A. M., Ahmad, S., Iezhitsa, I. N., Agarwal, R., Uskoković, V., & Mohamud, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.875662 · Cited by 77
“Clinical studies have shown a causal relationship between lower levels of BDNF and cognitive decline observed with aging, schizophrenia, and Rett syndrome (Zuccato et al., 2011; Autry and Monteggia, 2012; Soares et al., 2016).”
BackgroundEngineered BDNF producing cells as a potential treatment for neurologic disease
Deng, P., Anderson, J. D., Yu, A. S., Annett, G., Fink, K. D., & Nolta, J. A. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1183641 · Cited by 67
“[32,33] The BDNF protein is necessary for medium spiny neurons (MSNs) survival;[54] however, striatal neurons only produce very low levels of neurotrophic factors and are dependent on BDNF to be produced in the cerebral cortex and transported via corticostriatal tracts to MSNs.[59] While it has been reported in experi…”
BackgroundBrain-derived neurotrophic factor in substance use disorders: A systematic review and meta-analysis
Ornell, F. R., Hansen, F., Schuch, F. B., Rebelatto, F. P., Tavares, A. L. J., Scherer, J. N., Valério, A. G., Pechansky, F., Kessler, F. H. P., & DIEMEN, L. V. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.08.036 · Cited by 64
Liu, T., Im, W., Mook‐Jung, I., & Kim, M. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.156978 · Cited by 65
“Lower brain BDNF levels are detected in both HD patients and mouse models, and the loss of BDNF in the brain leads to more neuronal loss (Zuccato et al., 2001, 2011; Ciammola et al., 2007; Strand et al., 2007; Zuccato and Cattaneo, 2007), indicating an essential role of BDNF in the neuronal…”
BackgroundShpak, A. A., Guekht, A. B., Druzhkova, T. A., Kozlova, K. I., & Gulyaeva, N. V. (2017) · Current Eye Research · doi:10.1080/02713683.2017.1396617 · Cited by 67
Roth, C. L., Elfers, C., Gebhardt, U., Muller, H. L., & Reinehr, T. (2012) · Metabolism · doi:10.1016/j.metabol.2012.08.001 · Cited by 65
“Previous studies have shown that BDNF is sensitive to degradation over long term storage at both −20 and −80°F [59,60].”
BackgroundGutierrez, A. M., Corey‐Bloom, J., Thomas, E. A., & Desplats, P. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00335 · Cited by 62
Fluid and imaging biomarkers for Huntington's disease
Zeun, P., Scahill, R. I., Tabrizi, S. J., & Wild, E. J. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.004 · Cited by 61
Self-citationCreus‐Muncunill, J., & Ehrlich, M. E. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00782-9 · Cited by 57
A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward
Silajdžić, E., & Björkqvist, M. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170273 · Cited by 58
“The importance of standardising pre-analytical variables was clearly demonstrated in a study of BDNF in serum and plasma [189] where the authors found many issues concerning BDNF detection that make reliable measurement difficult.”
BackgroundPrimary cilia and autophagic dysfunction in Huntington’s disease
Kaliszewski, M., Knott, A. B., & Bossy-Wetzel, E. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.80 · Cited by 55
Fink, K. D., Rossignol, J., Crane, A. T., Davis, K., Bombard, M. C., Bavar, A. M., Clerc, S., Lowrance, S. A., Song, C., Lescaudron, L., et al. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt341 · Cited by 55
“BDNF production play a causal role in the progression of HD [31] and the increasing levels of BDNF may underscore behavioral sparing following MSC transplantation into rodent models of HD, the immune response to these cells also needs to be closely examined, as has been observed in other studies [7,8,27,29].”
ResultSerum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease
Huefner, A., Kuan, W., Mason, S., Mahajan, S., & Barker, R. A. (2019) · Chemical Science · doi:10.1039/c9sc03711j · Cited by 53
Lloret, A., & Beal, M. F. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02809-1 · Cited by 52
Brain-derived neurotrophic factor and airway fibrosis in asthma
Freeman, M., Sathish, V., Manlove, L. J., Wang, S., Britt, R. D., Thompson, M. A., Pabelick, C. M., & Prakash, Y. S. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00580.2016 · Cited by 52
Neuroprotective Effects of Psychotropic Drugs in Huntington’s Disease
Lauterbach, E. C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122558 · Cited by 52
“An analysis of BDNF mRNA and protein levels in the blood of patients with HD and presymptomatic HD unfortunately revealed no significant differences from human healthy controls [160], indicating that peripheral assessments of BDNF in patients with HD will not be suitable for future investigations.”
BackgroundRakotoarisoa, M., Angelov, B., Drechsler, M., Nicolas, V., Bizien, T., Gorshkova, Y. E., Deng, Y., & Angelova, A. (2022) · Smart Materials in Medicine · doi:10.1016/j.smaim.2022.03.001 · Cited by 52
A Glimpse of Molecular Biomarkers in Huntington’s Disease
Martínez, S. M., & Valor, L. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105411 · Cited by 51
“BDNF has emerged as a key factor in neuropathology, mostly in psychiatric disorders and neurodegenerative processes [81,82], and can be measured in the plasma and serum of patients affected by these conditions [83].”
BackgroundBritt, R. D., Thompson, M. A., Wicher, S. A., Manlove, L. J., Roesler, A. M., Fang, Y.-H., Roos, C. M., Smith, L., Miller, J. D., Pabelick, C. M., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801002r · Cited by 47
An update on Huntington's disease: from the gene to the clinic
Kim, S. D., & Fung, V. S. C. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000116 · Cited by 58
In vitro and in vivo models of H untington's disease show alterations in the endocannabinoid system
Bari, M., Battista, N., Valenza, M., Mastrangelo, N., Malaponti, M., Catanzaro, G., Centonze, D., Finazzi‐Agrò, A., Cattaneo, E. F., & Maccarrone, M. (2013) · FEBS Journal · doi:10.1111/febs.12329 · Cited by 51
Self-citationDeveloping Stem Cell Therapies for Juvenile and Adult-Onset Huntington's Disease
Fink, K. D., Deng, P., Torrest, A., Stewart, H., Pollock, K., Gruenloh, W., Annett, G., Tempkin, T., Wheelock, V., & Nolta, J. A. (2015) · Regenerative Medicine · doi:10.2217/rme.15.25 · Cited by 41
Kerkis, I., Haddad, M. S., Valverde, C. W., & Glosman, S. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0248-1 · Cited by 49
Fink, K. D., Deng, P., Torrest, A., Pollock, K., Dahlenburg, H., Annett, G., & Nolta, J. A. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.182682 · Cited by 43
“It has been reported that HD patients have lower levels of brain derived neurotrophic factor (BDNF) due to inhibition at the transcriptional level by the mutant huntingtin protein (Zuccato et al., 2011).”
BackgroundMaffioletti, E., Zanardini, R., Gennarelli, M., & Bocchio‐Chiavetto, L. (2014) · BioTechniques · doi:10.2144/000114204 · Cited by 46
Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis
Naegelin, Y., Säuberli, K., Schaedelin, S. A., Dingsdale, H., Magon, S., Baranzini, S. E., Amann, M., Parmar, K., Tsagkas, C., Calabrese, P., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51215 · Cited by 44
“In the past, lower serum BDNF levels in patients suffering from a number of neurological conditions compared to HC have been reported (such as depression,(31) schizophrenia,(32-38) Alzheimer’s,(39,40) or Huntington’s disease.(41,42) In autism spectrum disorders higher serum levels were found(43)).”
BackgroundSong, X., Quan, M., Lv, L., Li, X., Pang, L., Kennedy, D. N., Hodge, S. M., Harrington, A., Ziedonis, D. M., & Fan, X. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.009 · Cited by 43
“mentioned the reliability issue of measuring serum BDNF as a biomarker for Hungtinton's disease, as well as for patients of other illness conditions (Zuccato et al., 2011).”
BackgroundEffect of Clotting Duration and Temperature on BDNF Measurement in Human Serum
Amadio, P., Sandrini, L., Ieraci, A., Tremoli, E., & Barbieri, S. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091987 · Cited by 47
“It is important to pointing out that BDNF is usually measured in serum obtained after 1 h of clotting at RT [7,8,16].”
BackgroundNew Directions in Therapeutics for Huntington Disease
Potkin, K. T., & Potkin, S. G. (2018) · Future Neurology · doi:10.2217/fnl-2017-0035 · Cited by 35
“However, caution is warranted, as measuring BDNF in the peripheral blood may not be reliable [97].”
BackgroundWenceslau, C. V., de Souza, D. M., Mambelli-Lisboa, N. C., Ynoue, L. H., Araldi, R. P., da Silva, J. M., Pagani, E., Haddad, M. S., & Kerkis, I. (2022) · Cells · doi:10.3390/cells11101664 · Cited by 41
“Reduction in BDNF expression jeopardizes the longterm survival and morphology of striatal medium spiny neurons (MSN), causing striatal degeneration [29,54,55].”
BackgroundChapleau, C. A., Lane, J. B., Pozzo‐Miller, L. D., & Percy, A. K. (2013) · Current Clinical Pharmacology · doi:10.2174/15748847113086660069 · Cited by 36
mGluR5 regulates REST/NRSF signaling through N-cadherin/β-catenin complex in Huntington’s disease
de Souza, J. M., Abd‐Elrahman, K. S., Ribeiro, F. M., & Ferguson, S. S. G. (2020) · Molecular Brain · doi:10.1186/s13041-020-00657-7 · Cited by 55
Speidell, A. P., Abid, N. B., & Yano, H. (2023) · Biomedicines · doi:10.3390/biomedicines11082275 · Cited by 37
“More recent reports, however, conflict with earlier observations of decreased peripheral BDNF abundance in HD and further suggest that BDNF alone may not represent as a suitable biomarker for disease progression [87,88].”
ResultWhat, When and How to Measure—Peripheral Biomarkers in Therapy of Huntington’s Disease
Przybył, Ł., Woźna, M., Kozłowska, E., & Fiszer, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041561 · Cited by 34
“However, in other studies, no differences in serum or plasma BDNF levels were found between HD patients and healthy individuals [97,98].”
ResultKrzysztoń-Russjan, J., Zielonka, D., Jackiewicz, J., Kuśmirek, S., Bubko, I., Klimberg, A., Marcinkowski, T., & Anuszewska, E. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9479-3 · Cited by 34
“The reduction of the BDNF level had previously been described on a protein and transcript level in HD and also other neurodegenerative disorders, but a recent study confirms the phenomenon in HD only (Zuccato et al. 2011).”
ResultChang, K., Chen, Y., Wu, Y., Lee, W.-F., & Chen, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046492 · Cited by 39
Troncoso-Escudero, P., Sepúlveda, D., Pérez-Arancibia, R., Parra, A. V., Arcos, J., Grünenwald, F., & Vidal, R. L. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.571185 · Cited by 36
Biofluid Biomarkers in Huntington’s Disease
Rodrigues, F. B., Byrne, L. M., & Wild, E. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_17 · Cited by 32
“However, these findings were not corroborated in a larger study involving 398 indivuduals[130], mainly because, although blood concentration reflects at least partially in-brain concentration[131], this factor is also produced peripherally by megakaryocytes and platelets, and variations in blood collection, storage an…”
ResultSelf-citationThe Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease Mice
Hecklau, K., Mueller, S. G., Koch, S., Mehkary, M., Kilic, B., Harms, C., Boehm‐Sturm, P., & Yildirim, F. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.616886 · Cited by 31
“Accordingly, it has been shown that overexpression of Bdnf and Penk is neuroprotective and improves disease outcome in HD (Zuccato et al., 2005; Zuccato et al., 2011; Bissonnette et al., 2013).”
BackgroundBrain‑derived neurotrophic factor in autoimmune inflammatory diseases (Review)
Wang, N., & Tian, B. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10727 · Cited by 29
“This notion is in agreement with the study by Zuccato et al (60), who also demonstrated a time‑dependent change in serum BDNF levels due to different sample storage conditions.”
BackgroundResultThe updated development of blood-based biomarkers for Huntington’s disease
Zhang, S., Cheng, Y., & Shang, H. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11572-x · Cited by 30
BDNF Serum Levels with Respect to Multidimensional Assessment in Amyotrophic Lateral Sclerosis
Tremolizzo, L., Pellegrini, A., Conti, E., Arosio, A., Gerardi, F., Lunetta, C., Magni, P., Appollonio, I. M., & Ferrarese, C. (2016) · Neurodegenerative Diseases · doi:10.1159/000441916 · Cited by 30
Chen, G., Ma, Q., Goswami, D. B., Shang, J., & Miller, G. M. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13209 · Cited by 32
DNA Methylation in Huntington’s Disease
Zsindely, N., Siági, F., & Bodai, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312736 · Cited by 29
Astrocytes in Huntington’s Disease
Gray, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9913-8_14 · Cited by 32
PARP overactivation in neurological disorders
Arruri, V. K., Gundu, C., Khan, I., Khatri, D. K., & Singh, S. B. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06285-1 · Cited by 27
Antidepressants for neuroprotection in Huntington's disease: A review
Jamwal, S., & Kumar, P. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.10.033 · Cited by 30
Durbas, M., Horwacik, I., Boratyn, E., & Rokita, H. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3572 · Cited by 26
Nelson, M. L., Pfeifer, J. A., Hickey, J. P., Collins, A. E., & Kalisch, B. E. (2023) · Biology · doi:10.3390/biology12071042 · Cited by 25
“, proBDNF and mBDNF activate distinct receptors and signaling pathways that are linked with specific functions [128,143,144].”
BackgroundResultInfluentialLeschik, J., Eckenstaler, R., Nieweg, K., Lichtenecker, P., Brigadski, T., Gottmann, K., Leßmann, V., & Lutz, B. (2013) · Journal of Cell Science · doi:10.1242/jcs.135384 · Cited by 24
“J o u rn a l o f C e ll S c ie n c e Embryonic stem cells stably expressing BDNF–GFP exhibit a BDNF-release-dependent enhancement of neuronal differentiation”
BackgroundA kinetic model for Brain-Derived Neurotrophic Factor mediated spike timing-dependent LTP
Solinas, S. M. G., Edelmann, E., Leßmann, V., & Migliore, M. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006975 · Cited by 25
Factors affecting stability of plasma brain-derived neurotrophic factor
Wessels, J. M., Agarwal, R. K., Somani, A., Verschoor, C. P., Agarwal, S. K., & Foster, W. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-77046-6 · Cited by 21
Oikari, L. E., Yu, C., Okolicsanyi, R. K., Avgan, N., Peall, I. W., Griffiths, L. R., & Haupt, L. M. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24666 · Cited by 20
“The next day, the membrane was rinsed with TBST (Trisbuffered saline with 0.1% Tween-20) and horseradish peroxidase (HRP)-conjugated secondary antibodies (Table 3) diluted in 5% TA B L E 2 Q-PCR primer sequences Gene (Ref) Forward primer Reverse primer RefSeq BDNF (Zuccato et al., 2011) TAACGGCGGCAGACAAAAAGA GAAGTATTG…”
MethodInfluentialBuist, M., Fuss, D., & Rastegar, M. (2021) · Biomolecules · doi:10.3390/biom11081253 · Cited by 21
The Road from Nanomedicine to Precision Medicine
Rakotoarisoa, M., & Angelova, A. (2020) · doi:10.1201/9781003027010 · Cited by 19
Modelling the natural history of Huntington's disease progression
Kuan, W., Kasis, A., Yuan, Y., Mason, S., Lázár, A. S., Barker, R., & Gonçalves, J. M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308153 · Cited by 20
Sarabi, M., Perraud, A., Mazouffre, C., Nouaille, M., Jauberteau, M., & Mathonnet, M. (2016) · Biomedical Reports · doi:10.3892/br.2016.801 · Cited by 19
“However, the serum levels of BDNF are not informative with regard to Huntington's disease (5).”
Aqel, S., Ahmad, J., Saleh, I., Fathima, A., Thani, A. A. A., Mohamed, W. M. Y., & Shaito, A. A. (2025) · Biology · doi:10.3390/biology14020129 · Cited by 22
Wan, Y., & Kim, S. T. (2021) · International Ophthalmology · doi:10.1007/s10792-021-01959-y · Cited by 18
Bruno, A., Milillo, C., Anaclerio, F., Buccolini, C., Dell’Elice, A., Angilletta, I., Gatta, M., Ballerini, P., & Antonucci, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020976 · Cited by 18
“Zuccato and colleagues found no difference in the BDNF levels in serum and plasma in a large cohort of patients [129].”
BackgroundReview: The fate of cell grafts for the treatment of H untington's disease: the post‐mortem evidence
Cisbani, G., & Cicchetti, F. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12104 · Cited by 18
Radbakhsh, S., Butler, A. E., Moallem, S. A., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230602145817 · Cited by 17
Tian, B., Yang, C., Wang, J., Hou, X., Zhao, S., Li, Y., & Yang, P. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154764 · Cited by 18
Prion-like mechanisms in neurodegenerative disease: Implications for Huntington’s disease therapy
Srinageshwar, B., Petersen, R. B., Dunbar, G. L., & Rossignol, J. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0248 · Cited by 15
Dell’Oste, V., Palego, L., Betti, L., Fantasia, S., Gravina, D., Bordacchini, A., Pedrinelli, V., Giannaccini, G., & Carmassi, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063529 · Cited by 17
“The influence of many parameters can affect plasma BDNF measures [67]: different procedures in blood withdrawal, plasma separation and handling, centrifugation, temperature and plasma acidification may all impact final plasma BDNF results [42,65,85,86].”
BackgroundIs Serum BDNF Altered in Acute, Short- and Long-Term Recovered Restrictive Type Anorexia Nervosa?
Steinhäuser, J. L., King, J. A., Tam, F. I., Seidel, M., Biemann, R., Wronski, M., Geisler, D., Roessner, V., & Ehrlich, S. (2021) · Nutrients · doi:10.3390/nu13020432 · Cited by 14
“On the other hand, whether inferring central BDNF levels from the analysis of peripheral blood samples is appropriate is still subject to an ongoing debate [93,94] and could partly explain the null results from this current study.”
Regenerative medicine in Huntington’s disease: Strengths and weaknesses of preclinical studies
Tartaglione, A. M., Popoli, P., & Calamandrei, G. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.017 · Cited by 14
“In particular, Dey and co-workers (Dey et al., 2010) compared MSCs over-expressing BDNF, nerve growth factor (NGF) or their combination in YAC 128 transgenic mice.”
BackgroundInfluentialConforti, P., Besusso, D., Brocchetti, S., Campus, I., Cappadona, C., Galimberti, M., Laporta, A., Iennaco, R., Rossi, R. L., Bocchi, V. D., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105140 · Cited by 14
Self-citationAzman, K. F., & Zakaria, R. (2025) · Current Neuropharmacology · doi:10.2174/1570159x22666240530105516 · Cited by 13
“BDNF mRNA and protein levels in the blood or CSF were not significantly different between HD patients and controls [91, 92].”
Stepanova, P., Kumar, D., Cavonius, K., Korpikoski, J., Sirjala, J., Lindholm, D., & Voutilainen, M. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-28798-4 · Cited by 14
Lee, D. Y., Lee, S. E., Kwon, D. H., Nithiyanandam, S., Lee, M. H., Hwang, J. S., Basith, S., Ahn, J. H., Shin, T. H., & Lee, G. (2021) · Stem Cells International · doi:10.1155/2021/8444599 · Cited by 13
“have reported low BDNF levels in HD patients, and that these low levels, considered one component of disease pathophysiology, are less useful as a biomarker of disease onset and progression in HD patients [133].”
BackgroundThe Utility of BDNF Detection in Assessing Severity of Huntington’s Disease
Plinta, K., Plewka, A., Pawlicki, K., Zmarzły, N., Wójcik-Pędziwiatr, M., Rudziński, M., Krzak-Kubica, A., Doręgowska, M., & Rudzińska, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215181 · Cited by 13
Challenges of Huntington's disease and quest for therapeutic biomarkers
Kotrčová, E., Jarkovská, K., Valeková, I., Žižková, M. (., Motlík, J., Gadher, S. J., & Kovářová, H. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400073 · Cited by 12
Therapeutic Strategies for Huntington’s Disease
Mrzljak, L., & Muñoz-Sanjuán, I. (2013) · Current topics in behavioral neurosciences · doi:10.1007/7854_2013_250 · Cited by 13
“Therefore, the modulation of this pathway is a critical component of the therapeutic strategy for HD (Arenas et al. 1996; Arregui et al. 2011; Besusso et al. 2013; Brito et al. 2013; Buckley et al. 2010; Canals et al. 2004; Conforti 2013; Conforti et al. 2013; Giampa et al. 2013; Giralt et al. 2011; Goggi et al. 2002;…”
BackgroundSerum Brain-Derived Neurotrophic Factor in Glaucoma Patients in Japan: An Observational Study
Igarashi, T., Nakamoto, K., Kobayashi, M., Suzuki, H., Tobita, Y., Igarashi, T., Okuda, T., Okada, T., & Takahashi, H. (2020) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2020_87-605 · Cited by 12
Reference Genes Selection for Transcriptional Profiling in Blood of HD Patients and R6/2 Mice
Diamanti, D., Lahiri, N., Tarditi, A., Magnoni, L., Fondelli, C., Morena, E., Malusa, F., Pollio, G., Diodato, E., Tripepi, G., et al. (2013) · Journal of Huntington s Disease · doi:10.3233/jhd-120042 · Cited by 10
“The RT-qPCR primers were drawn inside the targeted region by Affymetrix probe sets, with the exception of human BDNF, human H2AFY (for which published primer sequences were used), SDHA, HPRT1 and HMBS (due to amplification efficiency identified by the software in a different region and to avoid template structure arte…”
BackgroundMethodInfluentialSelf-citationPlasma Brain-Derived Neurotrophic Factor and Psychopathology in Attempted Suicide
Ambrus, L., Sunnqvist, C., Ekman, R., Träskman‐Bendz, L., & Westrin, Å. (2016) · Neuropsychobiology · doi:10.1159/000446286 · Cited by 10
Mesenchymal stem cells for the treatment of cognitive impairment caused by neurological diseases
Qu, M., Xing, F., & Xing, N. (2022) · Biotechnology Letters · doi:10.1007/s10529-022-03274-7 · Cited by 9
Role of experience, training, and plasticity in the functional efficacy of striatal transplants
Döbrössy, M. D., & Nikkhah, G. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59575-1.00014-4 · Cited by 10
Metadata
- Authors
- Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E. J., Sassone, J., Ciammola, A., Bachoud-Lèvi, A. C., Tabrizi, S. J., Di Donato, S., & Cattaneo, E.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- National Hospital for Neurology and Neurosurgery (GB)
- IRCCS Istituto Auxologico Italiano (IT)
- Corresponding author
- Cattaneo, Elena
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-08-12
- Volume
- 6
- Issue
- 8
- Pages
- e22966
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3155522
- OpenAlex
- W2053424572
- Cited by
- 138
- References
- 35
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 3 · 2023: 10 · 2022: 7 · 2021: 16 · 2020: 17 · 2019: 10 · 2018: 11 · 2017: 9 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 11 · 2012: 5
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- CHDI Foundation
- National Institute for Health and Care Research (CL-2009-18-005)
- European Commission
- University College London Hospitals NHS Foundation Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- brain-derived neurotrophic factor, Huntington's disease, serum BDNF, plasma BDNF levels, neurodegeneration, measurement variability, disease progression
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antidepressive Agents, Tricyclic, Benzodiazepines, Enzyme-Linked Immunosorbent Assay, Female, France, Humans, Huntington Disease, Italy, London, Male, Middle Aged, RNA, Messenger, Antipsychotic Agents, Neurotransmitter Uptake Inhibitors, Cohort Studies, Gene Expression, Annexins, Brain-Derived Neurotrophic Factor, Reverse Transcriptase Polymerase Chain Reaction, rho-Associated Kinases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.